India, June 3 -- AIM ImmunoTech Inc. (AIM), an immune pharma company, announced the final enrolment of subjects in the Phase 2 clinical trial dubbed DURIPANC, evaluating AIM's drug Ampligen (rintatolimod) combined with AstraZeneca's Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer patients whose disease is stable after FOLFIRINOX treatment.
With the final subject having met the enrolment criteria, treatment is scheduled in mid-June according to the firm.
DURIPANC is an investigator-initiated, exploratory, open-label, single-centre study conducted through a collaboration among AIM ImmunoTech, AstraZeneca, and Erasmus Medical Centre in the Netherlands.
AIM ImmunoTech initially targeted July 2026 for this milestone, but...